CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioMimetic Therapeutics, LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioMimetic Therapeutics, LLC
389 Nichol Mill Lane
Phone: 615-844-1280p:615-844-1280 FRANKLIN, TN  37067  United States Ticker: BMTIBMTI

This company was Merged or Acquired on 10/1/2015.
This company ceased filing statements with the SEC on 3/15/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company’s Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company’s product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Larry W.Papasan 71 8/1/2005 8/1/2005
President, Chief Executive Officer, Director Samuel E.Lynch 52 8/1/2005 1/1/1999
Chief Financial Officer Lawrence E.Bullock 56 1/1/2004 1/1/2004
6 additional Officers and Directors records available in full report.

Business Names
Business Name
BioMimetic Therapeutics Canada, Inc.
BioMimetic Therapeutics Limited
BioMimetic Therapeutics Pty Ltd.
BioMimetic Therapeutics USA, Inc.
BMTI

General Information
Number of Employees: 75 (As of 12/31/2011)
Outstanding Shares: 28,225,241 (As of 11/14/2012)
Shareholders: 29
Stock Exchange: NASD
Federal Tax Id: 621786244
Fax Number: 615-844-1281


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, August 18, 2019